Status:
COMPLETED
Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer
Lead Sponsor:
Bar-Ilan University, Israel
Collaborating Sponsors:
Hematology and Oncology Specialists
Conditions:
Hot Flashes
Breast Cancer
Eligibility:
FEMALE
28-55 years
Phase:
NA
Brief Summary
This study evaluates the potential of a unique artificial intelligence-virtual reality intervention called Bubble, to reduce the number and intensity of hot flashes and their accompanying psychologica...
Detailed Description
Breast cancer is the most common cancer in women and the leading cause of death in women aged \< 55 years . Hot flashes are experienced by about 52% of perimenopausal women. After breast cancer, this ...
Eligibility Criteria
Inclusion
- Females between the ages of 18 and 60
- Having an existing diagnosis of breast or ovarian cancer
- Receiving standard-of-care chemotherapy, endocrine therapy or estrogen blocking anti-cancer treatment
- The woman reported experiencing hot flashes at least once per day for a duration of at least 7 days prior to the beginning of the study and hot flashes for at least 30 days prior to the beginning of the study
- No chronic migraine headaches, seizure disorders, serious vestibular disorders, or pathological vertigo
- No serious psychiatric disorders
- Not pregnant
- No current substance abuse
- Not participating in other forms of therapy
- Not using medical marijuana.
Exclusion
- \* women aged 28-55 with breast cancer suffering from hot flashes
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2019
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT04414033
Start Date
February 1 2018
End Date
February 28 2019
Last Update
January 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bar Ilan University
Ramat Gan, Israel